Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public by merging with a Cormorant-sponsored SPAC.

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

showed that a small molecule inhibitor specifically targeting KRAS G12D, the form of the mutation more commonly found in pancreatic cancer, stimulated the immune system while shrinking tumors or ...

In AsPC-1 (harboring KRAS G12D mutation): ~70% reduction in overall bioluminescence (an indication of tumor cell number) as compared to the control group, by day 28. In Panc-1 (harbouring KRAS ...